Adult ADHD Diagnosis in Australia: What criteria are needed, and what a prescribing doctor requires

Many adults arrive at an ADHD assessment after years of suspecting that something was different about how they think, work, and manage day-to-day life. Some have only recently come across descriptions of adult ADHD on social media. Others have been told for decades that they were lazy, sensitive, dramatic, or simply not trying hard enough. A formal assessment can be the first time someone receives a coherent account of why their experience has felt the way it has.

This article sets out what an adult ADHD diagnosis involves in Australia. It covers the diagnostic criteria, the assessment process, the role of childhood evidence, the differential conditions that need to be considered, and what a prescribing doctor needs to see in the assessment report before they can confidently prescribe medication.

I am Dr Sarah Fischer, Principal Psychologist at Behavioural Edge Psychology. I assess adults for ADHD using the methods and standards described below.

What ADHD looks like in adults

ADHD (Attention Deficit Hyperactivity Disorder) is a neurodevelopmental condition. The brain differences associated with ADHD are present from early in life and continue into adulthood for around two-thirds of people who had ADHD as children. Adult ADHD does not look the same as childhood ADHD.

Hyperactivity often becomes internal restlessness or mental noise rather than physical bouncing around. Inattention shows up as difficulty starting tasks, losing track of time, missing details, forgetting appointments, and chronic procrastination. Impulsivity may appear as interrupting, impulsive purchasing, blurting things out, or making sudden decisions without weighing the consequences.

For many adults, the most accurate description of ADHD is not a deficit of attention but a difficulty in regulating where attention goes, for how long, and at what cost. A person with ADHD can hyperfocus on something interesting for hours while being unable to start a routine task that they know matters. The challenge is regulation, not capacity.

The DSM-5-TR diagnostic criteria

In Australia, ADHD is diagnosed using the criteria set out in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). The ICD-11 criteria are similar and accepted in some clinical contexts. The DSM-5-TR framework requires five elements to be present.

Criterion A. A persistent pattern of symptoms

The first criterion requires a persistent pattern of inattention, hyperactivity-impulsivity, or both, that interferes with functioning or development. For adults aged 17 and over, at least five symptoms from the inattention list, or at least five symptoms from the hyperactivity-impulsivity list, must be present. The threshold is six or more symptoms for children and adolescents up to age 16. The lower adult threshold reflects research showing that ADHD symptoms reduce in number with age while remaining clinically meaningful.

Criterion B. Symptoms present before the age of 12

Several symptoms must have been present before the age of 12. This is the developmental criterion. ADHD is not a condition that begins in adulthood. It is a condition that has been present since childhood, even if it was not recognised at the time, even if it was masked by intelligence or compliance, and even if the adult has only patchy recall of their early years. The criterion was extended from age 7 to age 12 in DSM-5 based on evidence that around 95 per cent of adults with clinical ADHD features recall onset before age 12, compared with around 50 per cent who recall onset before age 7 (Applegate et al., 1997; Kessler et al., 2005).

Criterion C. Symptoms present in two or more settings

Several symptoms must be present in two or more settings. Examples include work, study, home life, social relationships, leisure activities, and self-management. ADHD is a pervasive pattern. A person who has difficulty concentrating only at work, but functions well across every other area of life, does not meet this criterion. ADHD that is restricted to one setting usually points to a different explanation, often something context-specific.

Criterion D. Clear evidence of functional impairment

There must be clear evidence that the symptoms interfere with, or reduce the quality of, social, academic, or occupational functioning. This is the impairment criterion. Difficulties that exist but cause no meaningful disruption to the person’s life, work, or relationships do not meet the diagnostic threshold. Functional impairment is the bridge between symptoms and a clinical diagnosis, and it is usually documented through specific examples rather than generic statements.

Criterion E. Not better explained by another condition

The symptoms must not be better explained by another mental disorder and must not occur exclusively during the course of schizophrenia or another psychotic disorder. This is the differential criterion, and it is where careful clinical reasoning matters most. Several other conditions can produce attention, concentration, and self-regulation difficulties. A diagnosis of ADHD requires those alternatives to have been considered and either ruled out or identified as comorbid.

Presentation types

DSM-5-TR distinguishes three presentation types based on which symptom cluster predominates. The predominantly inattentive presentation involves five or more inattention symptoms without enough hyperactive-impulsive symptoms to meet that threshold. The predominantly hyperactive-impulsive presentation involves the reverse. The combined presentation involves five or more symptoms from each cluster. Presentation type can shift across the lifespan, particularly from combined or hyperactive-impulsive in childhood to inattentive in adulthood.

A clinical principle worth holding on to. No rating scale, neuropsychological test, or biomarker can diagnose ADHD on its own. ADHD is diagnosed through clinical interview and clinical judgement, supported by structured measures and collateral information (Faraone et al., 2021).

Why adult ADHD is often missed

Several factors mean that ADHD has historically been under-diagnosed in adults, and particularly in women, in late-diagnosed individuals, and in people with the inattentive presentation.

Hyperactivity in childhood draws attention. A child running around a classroom is noticed. A child sitting quietly but daydreaming is not. The inattentive presentation is easy to miss, especially in children who are bright enough to manage academically despite their difficulties.

Girls and women tend to mask ADHD symptoms more often than boys and men, partly because the social cost of overt symptoms tends to be higher for girls. By the time a woman reaches her thirties or forties, she may have built a scaffolding of coping strategies (lists, alarms, exhausting effort, avoidance of demanding situations) that conceals the underlying difficulty from everyone around her, sometimes including herself.

Comorbidity is another reason ADHD is missed. Anxiety and depression often present more visibly than ADHD and tend to be treated first. Treatment for anxiety or depression may bring some relief but does not address the underlying ADHD. People can spend years in mental health treatment without the core condition being identified.

The expectation that ADHD looks like a young, restless boy is still common, including among some healthcare professionals. An assessment with a clinician who has experience in adult presentations, and particularly in female and non-binary phenotypes, makes a significant difference.

What a comprehensive assessment involves

A diagnostic ADHD assessment for adults typically takes two to three appointments, supported by a battery of standardised measures completed online between sessions.

The clinical interview

The clinical interview is the foundation of the assessment. It covers presenting concerns and the question that has brought the person in, developmental history (including academic trajectory and any childhood difficulties), occupational and relationship history, family psychiatric history, substance use, sleep and medical history, and prior psychological or psychiatric treatment. The interview is not a checklist. It is an extended conversation that builds a picture of how the person’s life has unfolded and how the symptoms have shaped that path.

The structured diagnostic interview (DIVA-5)

The structured diagnostic interview I use is the Diagnostic Interview for ADHD in Adults, 5th Edition (DIVA-5), developed by Kooij and Francken at PsyQ in the Netherlands. The DIVA-5 systematically evaluates all 18 DSM-5 ADHD criteria across both adulthood (past six months) and childhood (ages 5 to 12), with concrete behavioural examples for each criterion. It also assesses functional impairment across five life domains, covering work and education, relationships and family, social contacts, leisure and hobbies, and self-confidence and self-image. Administration takes around 60 to 90 minutes. Where possible, a partner or family member is included for the childhood history section.

Standardised rating scales

The standardised rating scales support the clinical formulation and provide normative comparisons. Rating scales cannot diagnose ADHD on their own. They quantify what the clinical interview is exploring. The scales I administer through NovoPsych include the Adult ADHD Self-Report Scale (ASRS) for current symptoms, the Wender Utah Rating Scale (WURS-25) for retrospective childhood symptoms, the Executive Skills Questionnaire Revised (ESQ-R) for everyday executive function difficulties, and the ADHD Clinical Outcome Scale (ACOS) for baseline severity that can be re-administered later to monitor treatment response.

Mood and anxiety screening is included as standard, using the Depression Anxiety Stress Scales (DASS-21) or equivalent instruments. Comorbidity screens are added where indicated. These may include the PCL-5 for post-traumatic stress, the ITQ for complex trauma, the CATI for autism, the MDQ for bipolar, and the K-10 for general distress.

Collateral information

Collateral information adds a layer of evidence that self-report alone cannot provide. The most useful sources are partners, parents, siblings, and contemporaneous documents such as school reports. Where direct sources are unavailable, the assessment uses retrospective rating scales with structured cueing, and indirect evidence (academic trajectory, early occupational patterns, the chronicity and pervasiveness of the symptom pattern) to build a defensible picture.

The role of childhood evidence

DSM-5-TR requires several symptoms to have been present before the age of 12. This is the part of the assessment that adults often find most difficult. Many people have limited recall of their childhood, and ADHD itself can impair the encoding and retrieval of episodic memories. Some clients also have trauma histories, were never recognised as struggling, or grew up in households where their behaviour was reframed as something other than ADHD.

A multi-source approach helps. Parents or siblings are interviewed where available. School reports and any prior psychological or paediatric assessments are reviewed. The WURS-25 provides a structured framework for retrospective recall using concrete behavioural examples rather than open-ended questions. Where direct evidence is limited, the assessment looks for indirect evidence, including academic trajectory, early occupational patterns, and the chronicity and pervasiveness of the symptom pattern across the lifespan.

The absence of clear childhood recall does not rule out ADHD. Poor childhood recall is a common feature of the condition itself, particularly in women and in high-achieving individuals who developed compensatory strategies that masked symptoms during childhood. A well-prepared assessment report addresses this directly rather than treating poor recall as evidence against the diagnosis.

Differential diagnosis

ADHD shares features with several other conditions. A careful differential diagnostic analysis is part of every assessment. The most common conditions that need to be considered are listed below.

• Anxiety disorders, where concentration difficulties can be a feature of generalised anxiety or panic.

• Depression, where low energy, slowed thinking, and difficulty initiating tasks can resemble ADHD.

• Post-traumatic stress and complex PTSD, where hypervigilance, attention difficulties, and emotional dysregulation overlap with ADHD.

• Autism spectrum, which involves a different attention profile and a different executive function pattern, and which often co-occurs with ADHD as AuDHD.

• Bipolar disorder, where mood-state-related attention changes can be mistaken for ADHD.

• Sleep disorders, where chronic sleep deprivation can mimic ADHD across the board.

• Substance use, where active substance effects can produce or mask ADHD symptoms.

• Thyroid or other medical conditions, which need to be ruled out by the prescribing clinician.

Comorbidity is the rule, not the exception. ADHD with anxiety is common. ADHD with depression is common. ADHD with autism (AuDHD) is increasingly recognised. ADHD with complex trauma is common. The role of the assessment is to identify all of the conditions that are present and to think clearly about what is driving what.

What a prescribing doctor needs to see

In Australia, psychologists diagnose ADHD. Psychologists do not prescribe medication. ADHD medication is prescribed by psychiatrists, paediatricians (for younger patients), and authorised general practitioners under specific arrangements in some states. A clinical psychology assessment is one of the most common pathways into a prescribing review.

A prescribing doctor needs the assessment report to give them everything required to make a confident prescribing decision. A report aligned to the Behavioural Edge Psychology protocol addresses the following elements.

• A DSM-5-TR diagnostic formulation with the presentation type identified (predominantly inattentive, predominantly hyperactive-impulsive, or combined).

• Evidence of childhood onset before age 12, with the specific source of that evidence identified (school reports, parent interview, retrospective rating scale, indirect evidence).

• Functional impairment across at least two settings, with specific real-world examples rather than generic statements.

• A differential diagnostic analysis showing which other conditions were considered, what was ruled out, and what is identified as comorbid.

• A comorbidity profile with treatment priority recommendations. If anxiety is severe and untreated, this matters for prescribing. If trauma is unprocessed, this matters too. The prescriber needs the full picture.

• A response validity assessment, including consistency analysis across the measures administered and clinical observations about engagement, effort, and presentation credibility during interview.

• A summary of collateral information and whether it is consistent with self-report.

• PBS eligibility information. This includes whether the diagnosis is retrospective (made after age 18) and what third-party evidence of childhood symptoms has been obtained.

• Treatment recommendations, including whether pharmacological intervention is supported, and any considerations the prescriber should weigh (substance use history, cardiovascular risk flags, comorbid conditions that may affect medication choice).

Scope of practice note

Physical health workup and cardiovascular risk assessment are outside the psychologist’s scope of practice. A well-prepared report explicitly recommends that the prescribing clinician complete these investigations before initiating pharmacotherapy. The Australian Prescriber (Suetani et al., 2026) specifies pre-prescribing checks of heart rate, blood pressure, weight, and bloods to exclude anaemia, thyroid dysfunction, and to establish baseline kidney and liver function.

The Australian regulatory and guideline framework

Australian ADHD assessment is anchored in several reference documents. The convergence between them is what gives the assessment its evidentiary weight.

The Australian Evidence-Based Clinical Practice Guideline for ADHD (AADPA, 2022) was approved by the NHMRC and endorsed by the RANZCP. It provides 132 recommendations covering ADHD across the lifespan and is the primary Australian reference for clinical practice. The RANZCP rescinded its own previous adult ADHD guideline in April 2024 in favour of the AADPA document.

The UK National Institute for Health and Care Excellence guideline NG87 (NICE, 2018, updated 2024) requires that ADHD diagnosis be made based on a full clinical and psychosocial assessment, a full developmental and psychiatric history, and observer reports. NICE NG87 also states explicitly that diagnosis should not be made solely based on rating scale or observational data.

The World Federation of ADHD International Consensus Statement (Faraone et al., 2021) compiled 208 empirically supported conclusions endorsed by 80 authors from 27 countries. It confirms that ADHD can only be diagnosed through clinical interview and cannot be diagnosed by rating scales alone, neuropsychological tests, or brain imaging.

These documents agree on the central point. ADHD diagnosis is a clinical decision made by a trained clinician based on converging evidence from interview, history, standardised measures, collateral information, and differential analysis. No single test diagnoses ADHD.

PBS eligibility for ADHD medication

The Pharmaceutical Benefits Scheme (PBS) subsidises some ADHD medications under specific conditions. The detail matters for adults who are seeking subsidised treatment, and a well-prepared assessment report addresses it directly.

Lisdexamfetamine (sold as Vyvanse) and long-acting methylphenidate (sold as Ritalin LA) are PBS-subsidised for individuals diagnosed before age 18, or for adults diagnosed retrospectively, provided that there is evidence of pre-existing childhood symptoms from a third-party source (parent, teacher, sibling, or other person who knew the individual in childhood).

Concerta (modified-release methylphenidate) is only PBS-subsidised for individuals diagnosed between ages 6 and 18.

Atomoxetine is only PBS-subsidised for individuals diagnosed between ages 6 and 18 who have a contraindication to, or are intolerant of, stimulant treatment.

Immediate-release methylphenidate (Ritalin) and dexamfetamine have no PBS age restrictions, but they are subject to jurisdictional Schedule 8 regulations and require an authority to prescribe in most Australian states.

For adults who were not diagnosed in childhood, the assessment report must clearly document what third-party evidence of childhood symptoms has been obtained, and the nature and source of that evidence. Where no informant or contemporaneous record is available, the report should document what was attempted, what alternative evidence supports childhood onset, and the clinical reasoning behind the diagnosis. Some prescribing psychiatrists will accept a well-documented clinical formulation that triangulates multiple indirect sources. Others may require more traditional collateral evidence. Transparency in the report allows the prescriber to make an informed decision about a PBS application.

What happens after diagnosis

A diagnostic assessment is the beginning of a process rather than the end. For many adults, the diagnosis itself produces a significant period of recalibration. Years of self-blame can shift quickly when someone is given a coherent neurodevelopmental account of their experience. This shift is often more important than any single treatment decision that follows.

Several pathways open up from the diagnostic report. A person may take the report to a GP for a referral to a psychiatrist for prescribing review. A person may pursue non-pharmacological supports such as ADHD-informed psychological therapy, coaching, workplace accommodations, or environmental restructuring. A person may request workplace adjustments under the Fair Work Act or NDIS supports if eligibility criteria are met. A person may return for outcome monitoring through the ACOS or other measures to track symptom and functional change over time.

A diagnosis is not a prescription. It is a framework for understanding and a basis for the decisions a person makes about their own treatment and life.

Adult ADHD assessment at Behavioural Edge Psychology

I offer adult ADHD assessments at Behavioural Edge Psychology, in person at Caulfield South and St Kilda, and via telehealth for clients across Australia. The assessment process is aligned to the AADPA Guideline (2022), NICE NG87, and the PBS eligibility framework, and produces a report designed to give a prescribing clinician everything they require to make a confident prescribing decision.

If you would like to discuss whether an assessment is right for you, you can find more information and contact options at www.behaviouraledgepsychology.com.

Frequently Asked Questions

What are the DSM-5-TR criteria for ADHD in adults in Australia?

ADHD in adults aged 17 and over requires at least five symptoms of inattention, at least five symptoms of hyperactivity-impulsivity, or both. Several symptoms must have been present before age 12. Symptoms must occur in two or more settings, must cause clear impairment to social, academic, or occupational functioning, and must not be better explained by another mental disorder.

Can a psychologist diagnose ADHD in Australia?

Yes. A general psychologist with appropriate training can diagnose ADHD in adults in Australia. No specific endorsement is required for ADHD diagnosis. Psychologists cannot prescribe medication. Medication is prescribed by psychiatrists, paediatricians for younger patients, and authorised general practitioners under specific state-based arrangements.

What is the gold-standard diagnostic interview for adult ADHD?

The Diagnostic Interview for ADHD in Adults, 5th Edition (DIVA-5), developed by Kooij and Francken, is widely used internationally. It systematically maps all 18 DSM-5 ADHD criteria across childhood and adulthood using concrete behavioural examples, and assesses functional impairment across five life domains.

What does a prescribing doctor need from a psychologist’s ADHD assessment report?

A prescribing doctor needs a DSM-5-TR diagnosis with presentation type, evidence of childhood onset before age 12 with source identified, functional impairment across at least two settings with specific examples, differential diagnostic reasoning, comorbidity profile and treatment priorities, response validity assessment, collateral summary, PBS eligibility information, and treatment recommendations including any medication considerations.

What is the AADPA Guideline for ADHD?

The Australian Evidence-Based Clinical Practice Guideline for Attention Deficit Hyperactivity Disorder, published by the Australasian ADHD Professionals Association in 2022, is the primary Australian reference for ADHD assessment and management. It was approved by the NHMRC and endorsed by the RANZCP, and contains 132 recommendations across the lifespan.

Can adult ADHD medication be subsidised by the PBS in Australia?

Yes, for eligible adults. Lisdexamfetamine (Vyvanse) and Ritalin LA are PBS-subsidised for adults diagnosed retrospectively after age 18, provided third-party evidence of childhood symptoms exists. Concerta and atomoxetine are restricted to individuals diagnosed between ages 6 and 18. Immediate-release methylphenidate and dexamfetamine have no PBS age restrictions but require a Schedule 8 authority to prescribe.

Why is adult ADHD often missed in women?

Women with ADHD often present with the inattentive subtype, which is less behaviourally disruptive and easier to overlook in childhood. Women also tend to mask symptoms more, building elaborate coping strategies that conceal the underlying difficulty. Comorbid anxiety and depression are commonly treated first, while the underlying ADHD remains unidentified. The historical research focus on young male presentations has also contributed to under-diagnosis in women.

How long does an adult ADHD assessment take in Australia?

A comprehensive adult ADHD assessment typically requires two to three sessions over several weeks, totalling around 3 to 5 hours of clinical contact, plus online questionnaires completed between sessions and time for report preparation. Most assessments are completed within four to six weeks from intake.

What does the age 12 criterion mean for ADHD diagnosis?

DSM-5-TR requires several ADHD symptoms to have been present before the age of 12. This criterion replaced the earlier age 7 threshold used in DSM-IV and was based on evidence that approximately 95 per cent of adults with clinical ADHD features recall onset before age 12, compared with around 50 per cent who recall onset before age 7. The criterion does not require formal diagnosis in childhood, only evidence that symptoms were present.

Can ADHD be diagnosed by a rating scale or brain scan?

No. The World Federation of ADHD International Consensus Statement (Faraone et al., 2021) and NICE NG87 both state that ADHD can only be diagnosed through clinical interview and clinical judgement. Rating scales, neuropsychological tests, and brain imaging are adjunctive. They cannot diagnose or rule out ADHD on their own.

Selected references

• Applegate, B., Lahey, B. B., Hart, E. L., et al. (1997). Validity of the age-of-onset criterion for ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 36(9), 1211 to 1221.

• Australasian ADHD Professionals Association (AADPA). (2022). Australian Evidence-Based Clinical Practice Guideline for Attention Deficit Hyperactivity Disorder. Melbourne, Australia.

• Australasian ADHD Professionals Association (AADPA). (2024). ADHD Prescribing Guide for Australian Healthcare Professionals. Melbourne, Australia.

• Faraone, S. V., Banaschewski, T., Coghill, D., et al. (2021). The World Federation of ADHD International Consensus Statement, 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 128, 789 to 818.

• Kessler, R. C., Adler, L., Ames, M., et al. (2005). The World Health Organization Adult ADHD Self-Report Scale (ASRS). Psychological Medicine, 35(2), 245 to 256.

• Kooij, J. J. S., and Francken, M. H. (2019). DIVA-5, Diagnostic Interview for ADHD in Adults, 5th Edition. DIVA Foundation, The Netherlands.

• National Institute for Health and Care Excellence (NICE). (2018, updated 2024). Attention deficit hyperactivity disorder, diagnosis and management (NG87). London, UK.

• Suetani, S., Hull, J., and Scott, J. G. (2026). Pharmacological management of attention deficit hyperactivity disorder in adults. Australian Prescriber, 49, 10 to 15.